Prognostic factors in definitive radiotherapy of uterine cervical cancer
- PMID: 12807246
Prognostic factors in definitive radiotherapy of uterine cervical cancer
Abstract
Purpose: To determine the prognostic factors related to local control and survival in 257 patients with uterine cervical cancer treated with definitive radiotherapy (RT).
Materials and methods: The medical records of 257 patients treated with definitive RT from January 1987 to December 1998 were reviewed retrospectively. Pretreatment and treatment parameters were analyzed to determine their prognostic value onlocal control and survival. Survival analyses were performed using the Kaplan-Meier method. The log-rank test was used for univariate analyses and the Cox regression model was used for multivariate analyses.
Results: Median age was 55 (range 25-82). Squamous cell carcinoma was the most common histologic type (89.1%). The distribution per FIGO Stage was IIA: 13.2%; IIB: 54.9%; IIIA: 3.9%; IIIB: 19.8%; IVA: 8.2%. Ninety-eight patients (38.1%) were treated with external RT alone; 134 (52.1%) received both external RT and intracavitary brachytherapy; 21 (8.2%) received external RT and chemotherapy and four (1.6%) received external RT, intracavitary brachytherapy and chemotherapy. Median follow-up duration was 50 months (range 24-155 months). The failure rate was 51.8% with 26.5% of patients having only local failure, 16.7% only distant failure and 8.6% both local and distant failure. Five-year local progression-free, disease-free and overall survival rates were 58.1%, 44% and 63.7%, respectively. In univariate analysis the prognostic factors identified for local progression-free survival were histology (p = 0.008), FIGO stage (p < 0.001), initial hemoglobin (Hgb) level (p = 0.001), total radiation dose (p = 0.039), use of brachytherapy (p = 0.001) and of chemotherapy (p = 0.037) and enlarged paraaortic nodes (p = 0.016). In multivariate analysis the prognostic factors were FIGO stage (p = 0.014), initial Hgb level (p = 0.040), and use of brachytherapy (p = 0.013). The prognostic factors identified for disease-free survival were histology (p = 0.011), FIGO stage (p < 0.001), initial Hgb level (p < 0.001), use of brachytherapy (p = 0.001) and of chemotherapy (p = 0.014) in univariate analysis; and FIGO stage (p < 0.001), initial Hgb level (p = 0.017), total tumor dose (p = 0.034), use of brachytherapy (p = 0.006) and of chemotherapy (p = 0.021) in multivariate analysis. Factors influencing overall survival were FIGO stage (p < 0.001), initial Hgb level (p = 0.006), overall treatment time (p = 0.028), total tumor dose (p = 0.007), use of brachytherapy (p < 0.001), enlarged paraaortic (p < 0.001) and pelvic nodes (p = 0.004) in univariate analysis; and FIGO stage (p < 0.001), overall treatment time (p = 0.031), enlarged paraaortic (p = 0.007) and pelvic lymph nodes (p = 0.043) in multivariate analysis.
Conclusion: Definitive RT is an effective treatment for patients with uterine cervical cancer. There are many prognostic factors influencing treatment outcome. Brachytherapy and chemotherapy must be added in appropriate patients to improve the outcome. Future prospective trials should be undertaken to confirm the validity of these factors and to individualize the treatment strategy for every patient.
Similar articles
-
The adverse effect of treatment prolongation in cervical cancer by high-dose-rate intracavitary brachytherapy.Radiother Oncol. 2003 Apr;67(1):69-76. doi: 10.1016/s0167-8140(02)00439-5. Radiother Oncol. 2003. PMID: 12758242
-
Prognostic factors in patients with carcinoma of the uterine cervix treated with external beam irradiation and IR-192 high-dose-rate brachytherapy.Int J Radiat Oncol Biol Phys. 1998 Oct 1;42(3):531-40. doi: 10.1016/s0360-3016(98)00255-7. Int J Radiat Oncol Biol Phys. 1998. PMID: 9806511
-
High dose-rate brachytherapy for elderly patients with uterine cervical cancer.Jpn J Clin Oncol. 2003 May;33(5):221-8. doi: 10.1093/jjco/hyg041. Jpn J Clin Oncol. 2003. PMID: 12865465
-
Treatment results of high-dose-rate remote afterloading brachytherapy for cervical cancer and retrospective comparison of two regimens.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1254-64. doi: 10.1016/s0360-3016(02)04525-x. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654435 Review.
-
An audit of the treatment of carcinoma of the uterine cervix using external beam radiotherapy and a single line source brachytherapy technique.Br J Radiol. 1997 Dec;70(840):1259-69. doi: 10.1259/bjr.70.840.9505845. Br J Radiol. 1997. PMID: 9505845 Review.
Cited by
-
Tumour-Related Parameters as a Prognostic Factor in Patients with Advanced Cervical Cancer: 20-Year Follow-Up of Diagnostic and Treatment Changes during Chemioradiotherapy.J Pers Med. 2022 Oct 15;12(10):1722. doi: 10.3390/jpm12101722. J Pers Med. 2022. PMID: 36294861 Free PMC article.
-
Prophylactic extended-field irradiation with concurrent chemotherapy for pelvic lymph node-positive cervical cancer.Radiat Oncol J. 2017 Dec;35(4):349-358. doi: 10.3857/roj.2017.00367. Epub 2017 Dec 23. Radiat Oncol J. 2017. PMID: 29262671 Free PMC article.
-
Local Radiotherapy or Chemotherapy for Oligo-recurrent Cervical Cancer in Patients With Prior Pelvic Irradiation.In Vivo. 2019 Sep-Oct;33(5):1659-1665. doi: 10.21873/invivo.11652. In Vivo. 2019. PMID: 31471420 Free PMC article.
-
Early response and local control of stage I non-small-cell lung cancer after stereotactic radiotherapy: difference by histology.Cancer Sci. 2013 Jan;104(1):130-4. doi: 10.1111/cas.12048. Epub 2012 Dec 4. Cancer Sci. 2013. PMID: 23095036 Free PMC article.
-
Computed tomography-based radiomics modeling to predict patient overall survival in cervical cancer with intensity-modulated radiotherapy combined with concurrent chemotherapy.J Int Med Res. 2025 Mar;53(3):3000605251325996. doi: 10.1177/03000605251325996. Epub 2025 Mar 22. J Int Med Res. 2025. PMID: 40119689 Free PMC article.